Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This inactivated poliomyelitis vaccine (IPV) is a trivalent biologic developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) using the traditional Salk strains (Type 1 Mahoney, Type 2 MEF-1, and Type 3 Saukett). The vaccine is produced by growing the viruses in Vero cells or primary monkey kidney cells, followed by purification and inactivation with formaldehyde. It is designed to provide active immunity against all three serotypes of poliovirus, preventing paralytic poliomyelitis. In clinical development within China, this Salk-strain IPV has served as a critical benchmark for evaluating the safety and immunogenicity of newer Sabin-strain based inactivated vaccines (sIPV).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Inactivated Poliomyelitis Vaccine (Salk strains) (IMBCAMS).